Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on novel serotonergic agonists for mental health conditions, announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. This announcement comes as the company advances its lead candidate, HLP003, through Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD), a condition affecting millions worldwide.
The Jefferies conference is a premier event that brings together industry leaders, investors, and analysts to discuss emerging trends and investment opportunities in healthcare. For Helus Pharma, this platform offers an opportunity to showcase its proprietary NSA (novel serotonergic agonist) pipeline, which includes HLP003 and HLP004, the latter in Phase 2 for generalized anxiety disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status that expedites development and review for drugs that demonstrate substantial improvement over existing therapies. This designation highlights the potential of HLP003 to address the large unmet need for patients who do not respond adequately to standard antidepressants.
The company’s approach centers on synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity—the brain’s ability to adapt and form new neural connections. Unlike traditional antidepressants that may take weeks to work, NSAs aim to provide rapid and durable improvements in mental health. According to the World Health Organization, depression is a leading cause of disability globally, and current treatments often fall short for many patients. Helus Pharma’s focus on adjunctive treatment means HLP003 could be used alongside existing therapies, potentially offering a new option for those with treatment-resistant depression.
Investors and analysts will be keen to hear updates on the Phase 3 trial for HLP003, including enrollment timelines and data readouts. The company also maintains an extensive research portfolio of investigational NSAs, suggesting a long-term commitment to expanding its pipeline. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland, and its shares are listed on both NASDAQ and Cboe Canada.
The fireside chat is expected to cover the company’s strategic priorities, clinical progress, and market opportunity. A live webcast and replay will be accessible via the company’s investor relations website at https://ibn.fm/1QdP7. For more details on Helus Pharma and its pipeline, visit www.helus.com.
